BACKGROUND: This study was conducted to examine the pharmacokinetic interactions between buprenorphine/naloxone (BUP/NLX) and lopinavir/ritonavir (LPV/r) in HIV-seronegative subjects chronically maintained on BUP/NLX. METHODS: This study was an open labeled pharmacokinetic study in twelve HIV-seronegative subjects stabilized on at least 3 weeks of BUP/NLX therapy. Subjects sequentially underwent baseline and steady-state pharmacokinetic evaluation of once-daily LPV/r (800/200 mg). RESULTS: Compared to baseline values, BUP AUC0-24h (46.8 vs. 46.2 ng*hr/mL) and Cmax (6.54 vs. 5.88 ng/mL) did not differ significantly after achieving steady-state LPV/r. Similar analyses of norBUP, the primary metabolite of BUP, demonstrated no significant difference in norBUP AUC0-24 hours (73.7 vs. 52.7 ng x h/mL); however, Cmax (5.29 vs. 3.11 ng/mL) levels were statistically different (P < 0.05) after LPV/r administration. Naloxone concentrations were similarly unchanged for AUC0-24 hours (0.421 vs. 0.374 ng x hr/mL) and Cmax (0.186 vs. 0.186 ng/mL). Using standardized measures, no objective opioid withdrawal was observed. The AUC0-24 hours and Cmin of LPV in this study did not significantly differ from historical controls (159.6 vs. 171.3 microg x hr/mL) and (2.3 vs. 1.3 microg/mL). CONCLUSIONS: The addition of LPV/r to stabilized patients receiving BUP/NLX did not affect buprenorphine pharmacokinetics but did increase the clearance of norbuprenorphine. Pharmacodynamic responses indicate that the altered norbuprenorphine clearance did not lead to opioid withdrawal. Buprenorphine/naloxone and LPV/r can be safely coadministered without need for dosage modification.
BACKGROUND: This study was conducted to examine the pharmacokinetic interactions between buprenorphine/naloxone (BUP/NLX) and lopinavir/ritonavir (LPV/r) in HIV-seronegative subjects chronically maintained on BUP/NLX. METHODS: This study was an open labeled pharmacokinetic study in twelve HIV-seronegative subjects stabilized on at least 3 weeks of BUP/NLX therapy. Subjects sequentially underwent baseline and steady-state pharmacokinetic evaluation of once-daily LPV/r (800/200 mg). RESULTS: Compared to baseline values, BUP AUC0-24h (46.8 vs. 46.2 ng*hr/mL) and Cmax (6.54 vs. 5.88 ng/mL) did not differ significantly after achieving steady-state LPV/r. Similar analyses of norBUP, the primary metabolite of BUP, demonstrated no significant difference in norBUP AUC0-24 hours (73.7 vs. 52.7 ng x h/mL); however, Cmax (5.29 vs. 3.11 ng/mL) levels were statistically different (P < 0.05) after LPV/r administration. Naloxone concentrations were similarly unchanged for AUC0-24 hours (0.421 vs. 0.374 ng x hr/mL) and Cmax (0.186 vs. 0.186 ng/mL). Using standardized measures, no objective opioid withdrawal was observed. The AUC0-24 hours and Cmin of LPV in this study did not significantly differ from historical controls (159.6 vs. 171.3 microg x hr/mL) and (2.3 vs. 1.3 microg/mL). CONCLUSIONS: The addition of LPV/r to stabilized patients receiving BUP/NLX did not affect buprenorphine pharmacokinetics but did increase the clearance of norbuprenorphine. Pharmacodynamic responses indicate that the altered norbuprenorphine clearance did not lead to opioid withdrawal. Buprenorphine/naloxone and LPV/r can be safely coadministered without need for dosage modification.
Authors: G N Kumar; J Dykstra; E M Roberts; V K Jayanti; D Hickman; J Uchic; Y Yao; B Surber; S Thomas; G R Granneman Journal: Drug Metab Dispos Date: 1999-08 Impact factor: 3.922
Authors: Bregt S Kappelhoff; Kristel M L Crommentuyn; Monique M R de Maat; Jan W Mulder; Alwin D R Huitema; Jos H Beijnen Journal: Clin Pharmacokinet Date: 2004 Impact factor: 6.447
Authors: Kim Keil; Jill Hochreitter; Robin DiFrancesco; Barry S Zingman; Richard C Reichman; Margaret A Fischl; Barbara Gripshover; Gene D Morse Journal: Ther Drug Monit Date: 2007-02 Impact factor: 3.681
Authors: Elinore F McCance-Katz; David E Moody; Patrick F Smith; Gene D Morse; Gerald Friedland; Patricia Pade; Jennifer Baker; Anika Alvanzo; Peter Jatlow; Petrie M Rainey Journal: Clin Infect Dis Date: 2006-12-15 Impact factor: 9.079
Authors: C J L la Porte; E P H Colbers; R Bertz; D S Voncken; K Wikstrom; M J Boeree; P P Koopmans; Y A Hekster; D M Burger Journal: Antimicrob Agents Chemother Date: 2004-05 Impact factor: 5.191
Authors: David E Moody; Matthew H Slawson; Eric C Strain; John D Laycock; Alan C Spanbauer; Rodger L Foltz Journal: Anal Biochem Date: 2002-07-01 Impact factor: 3.365
Authors: R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland Journal: Expert Rev Clin Pharmacol Date: 2013-05 Impact factor: 5.045
Authors: Kenneth Blum; Thomas J H Chen; John Bailey; Abdalla Bowirrat; John Femino; Amanda L C Chen; Thomas Simpatico; Siobhan Morse; John Giordano; Uma Damle; Mallory Kerner; Eric R Braverman; Frank Fornari; B William Downs; Cynthia Rector; Debmayla Barh; Marlene Oscar-Berman Journal: Mol Neurobiol Date: 2011-09-24 Impact factor: 5.590
Authors: Qing Ma; Barry S Zingman; Amneris E Luque; Margaret A Fischl; Barbara M Gripshover; Charles S Venuto; Robin DiFrancesco; Alan Forrest; Gene D Morse Journal: Ther Drug Monit Date: 2011-06 Impact factor: 3.681
Authors: Mari Fihlman; Tuija Hemmilä; Nora M Hagelberg; Janne T Backman; Jouko Laitila; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola; Teijo I Saari Journal: Eur J Clin Pharmacol Date: 2018-08-30 Impact factor: 2.953
Authors: Mari Fihlman; Tuija Hemmilä; Nora M Hagelberg; Kristiina Kuusniemi; Janne T Backman; Jouko Laitila; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola; Teijo I Saari Journal: Eur J Clin Pharmacol Date: 2016-08-10 Impact factor: 2.953
Authors: Kenneth Blum; Marlene Oscar-Berman; John Femino; Roger L Waite; Lisa Benya; John Giordano; Joan Borsten; William B Downs; Eric R Braverman; Raquel Loehmann; Kristina Dushaj; David Han; Thomas Simpatico; Mary Hauser; Debmalya Barh; Thomas McLaughlin Journal: J Addict Res Ther Date: 2013-04-23
Authors: Andrew H Talal; Yuxin Ding; Charles S Venuto; Lindsay M Chakan; Anthony McLeod; Arpan Dharia; Gene D Morse; Lawrence S Brown; Marianthi Markatou; Evan D Kharasch Journal: PLoS One Date: 2020-04-17 Impact factor: 3.240